<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Organogenesis Holdings Inc — News on 6ix</title>
    <link>https://6ix.com/company/organogenesis-holdings-inc</link>
    <description>Latest news and press releases for Organogenesis Holdings Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/organogenesis-holdings-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a71778dffbe2df10bc93.webp</url>
      <title>Organogenesis Holdings Inc</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc</link>
    </image>
    <item>
      <title>Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-completes-rolling-submission-of-biologics-license-application-for-renur</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-completes-rolling-submission-of-biologics-license-application-for-renur</guid>
      <pubDate>Tue, 28 Apr 2026 04:00:00 GMT</pubDate>
      <description>If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain CANTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) --</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2026-financial-results-on-may-7-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2026-financial-results-on-may-7-2026</guid>
      <pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
      <description>CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company</description>
    </item>
    <item>
      <title>Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-achieves-primary-endpoint-in-randomized-controlled-trial-of-puraplyram</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-achieves-primary-endpoint-in-randomized-controlled-trial-of-puraplyram</guid>
      <pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
      <description>Statistically significant</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-reports-fourth-quarter-2025-financial-results-posts-record-revenue</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-reports-fourth-quarter-2025-financial-results-posts-record-revenue</guid>
      <pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
      <description>CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2025-financial-results-on-february-26-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-to-report-fourth-quarter-and-fiscal-year-2025-financial-results-on-february-26-2026</guid>
      <pubDate>Thu, 19 Feb 2026 21:05:00 GMT</pubDate>
      <description>CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th. Management will host a conference call at 5:00 p.m. Eastern Time on Fe</description>
    </item>
    <item>
      <title>Organogenesis Announces Initiation of Biologics License Application for ReNu®</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-announces-initiation-biologics-license-application-renur-2025-12-23</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-announces-initiation-biologics-license-application-renur-2025-12-23</guid>
      <pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
      <description>Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) --</description>
    </item>
    <item>
      <title>Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-announces-successful-fda-meeting-and-plan-file-bla-renur-knee</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-announces-successful-fda-meeting-and-plan-file-bla-renur-knee</guid>
      <pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
      <description>Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-reports-third-quarter-2025-financial-results-posts-record</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-reports-third-quarter-2025-financial-results-posts-record</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>CANTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the</description>
    </item>
    <item>
      <title>Organogenesis Applauds CMS’s Significant Step In Payment Reform</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-applauds-cmss-significant-step-payment-reform-2025-11-03</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-applauds-cmss-significant-step-payment-reform-2025-11-03</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-announces-inducement-grants-under-nasdaq-listing-rule</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-announces-inducement-grants-under-nasdaq-listing-rule</guid>
      <pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
      <description>CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-report-third-quarter-fiscal-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-report-third-quarter-fiscal-year-2025-financial-results</guid>
      <pubDate>Wed, 01 Oct 2025 04:00:00 GMT</pubDate>
      <description>CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the</description>
    </item>
    <item>
      <title>Organogenesis Provides Update on Second Phase 3 ReNu® Study</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-provides-update-second-phase-3-renur-study-2025-09-25</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-provides-update-second-phase-3-renur-study-2025-09-25</guid>
      <pubDate>Thu, 25 Sep 2025 04:00:00 GMT</pubDate>
      <description>Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-participate-upcoming-investor-conferences-september-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-participate-upcoming-investor-conferences-september-2025</guid>
      <pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
      <description>CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-reports-second-quarter-2025-financial-results-2025-08-07</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-reports-second-quarter-2025-financial-results-2025-08-07</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-report-second-quarter-fiscal-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-report-second-quarter-fiscal-year-2025-financial-results</guid>
      <pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
      <description>CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the</description>
    </item>
    <item>
      <title>Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-applauds-cms-proposal-reform-skin-substitute-payment-policy-urges</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-applauds-cms-proposal-reform-skin-substitute-payment-policy-urges</guid>
      <pubDate>Tue, 15 Jul 2025 04:00:00 GMT</pubDate>
      <description>CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-reports-first-quarter-2025-financial-results-2025-05-08</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-reports-first-quarter-2025-financial-results-2025-05-08</guid>
      <pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
      <description>CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the</description>
    </item>
    <item>
      <title>Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-supports-cms-local-coverage-determination-implementation-delay-review</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-supports-cms-local-coverage-determination-implementation-delay-review</guid>
      <pubDate>Fri, 11 Apr 2025 04:00:00 GMT</pubDate>
      <description>Organogenesis recommends CMS also implement an integrated coverage and payment policy CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-report-first-quarter-fiscal-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-report-first-quarter-fiscal-year-2025-financial-results</guid>
      <pubDate>Mon, 07 Apr 2025 04:00:00 GMT</pubDate>
      <description>CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the</description>
    </item>
    <item>
      <title>Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results</title>
      <link>https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-reports-fourth-quarter-2024-financial-results-2025-02-27</link>
      <guid isPermaLink="true">https://6ix.com/company/organogenesis-holdings-inc/news/organogenesis-holdings-inc-reports-fourth-quarter-2024-financial-results-2025-02-27</guid>
      <pubDate>Thu, 27 Feb 2025 05:00:00 GMT</pubDate>
      <description>CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company</description>
    </item>
  </channel>
</rss>